These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 29356543)

  • 1. Site-Specifically Labeled Antibody-Drug Conjugate for Simultaneous Therapy and ImmunoPET.
    Adumeau P; Vivier D; Sharma SK; Wang J; Zhang T; Chen A; Agnew BJ; Zeglis BM
    Mol Pharm; 2018 Mar; 15(3):892-898. PubMed ID: 29356543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with
    Al-Saden N; Lam K; Chan C; Reilly RM
    Mol Pharm; 2018 Aug; 15(8):3383-3393. PubMed ID: 29957952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Influence of Glycans-Specific Bioconjugation on the FcγRI Binding and
    Vivier D; Fung K; Rodriguez C; Adumeau P; Ulaner GA; Lewis JS; Sharma SK; Zeglis BM
    Theranostics; 2020; 10(4):1746-1757. PubMed ID: 32042334
    [No Abstract]   [Full Text] [Related]  

  • 4. Imaging of HER2 with [
    Massicano AVF; Lee S; Crenshaw BK; Aweda TA; El Sayed R; Super I; Bose R; Marquez-Nostra BV; Lapi SE
    Cancer Biother Radiopharm; 2019 May; 34(4):209-217. PubMed ID: 30676778
    [No Abstract]   [Full Text] [Related]  

  • 5. Chemoenzymatic strategy for the synthesis of site-specifically labeled immunoconjugates for multimodal PET and optical imaging.
    Zeglis BM; Davis CB; Abdel-Atti D; Carlin SD; Chen A; Aggeler R; Agnew BJ; Lewis JS
    Bioconjug Chem; 2014 Dec; 25(12):2123-8. PubMed ID: 25418333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Anti-LGR5 Antibodies by ImmunoPET for Imaging Colorectal Tumors and Development of Antibody-Drug Conjugates.
    Azhdarinia A; Voss J; Ghosh SC; Simien JA; Hernandez Vargas S; Cui J; Yu WA; Liu Q; Carmon KS
    Mol Pharm; 2018 Jun; 15(6):2448-2454. PubMed ID: 29718672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lysine-Directed Site-Selective Bioconjugation for the Creation of Radioimmunoconjugates.
    Sarrett SM; Rodriguez C; Rymarczyk G; Hosny MM; Keinänen O; Delaney S; Thau S; Krantz BA; Zeglis BM
    Bioconjug Chem; 2022 Sep; 33(9):1750-1760. PubMed ID: 35946495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluorine-18 labeling of an anti-HER2 VHH using a residualizing prosthetic group via a strain-promoted click reaction: Chemistry and preliminary evaluation.
    Zhou Z; Chitneni SK; Devoogdt N; Zalutsky MR; Vaidyanathan G
    Bioorg Med Chem; 2018 May; 26(8):1939-1949. PubMed ID: 29534937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors.
    Lütje S; Gerrits D; Molkenboer-Kuenen JD; Herrmann K; Fracasso G; Colombatti M; Boerman OC; Heskamp S
    J Nucl Med; 2018 Mar; 59(3):494-501. PubMed ID: 29146698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER2-Targeted PET Imaging and Therapy of Hyaluronan-Masked HER2-Overexpressing Breast Cancer.
    Pereira PMR; Ragupathi A; Shmuel S; Mandleywala K; Viola NT; Lewis JS
    Mol Pharm; 2020 Jan; 17(1):327-337. PubMed ID: 31804840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretargeted PET Imaging Using a Site-Specifically Labeled Immunoconjugate.
    Cook BE; Adumeau P; Membreno R; Carnazza KE; Brand C; Reiner T; Agnew BJ; Lewis JS; Zeglis BM
    Bioconjug Chem; 2016 Aug; 27(8):1789-95. PubMed ID: 27356886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Impact of FcγRI Binding on Immuno-PET.
    Vivier D; Sharma SK; Adumeau P; Rodriguez C; Fung K; Zeglis BM
    J Nucl Med; 2019 Aug; 60(8):1174-1182. PubMed ID: 30733320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical Efficacy of an Antibody-Drug Conjugate Targeting Mesothelin Correlates with Quantitative 89Zr-ImmunoPET.
    Terwisscha van Scheltinga AG; Ogasawara A; Pacheco G; Vanderbilt AN; Tinianow JN; Gupta N; Li D; Firestein R; Marik J; Scales SJ; Williams SP
    Mol Cancer Ther; 2017 Jan; 16(1):134-142. PubMed ID: 27760836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER2-targeted antibody drug conjugates for ovarian cancer therapy.
    Jiang J; Dong L; Wang L; Wang L; Zhang J; Chen F; Zhang X; Huang M; Li S; Ma W; Xu Q; Huang C; Fang J; Wang C
    Eur J Pharm Sci; 2016 Oct; 93():274-86. PubMed ID: 27509865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ImmunoPET Imaging of Endogenous and Transfected Prolactin Receptor Tumor Xenografts.
    Cheal SM; Ruan S; Veach DR; Longo VA; Punzalan BJ; Wu J; Fung EK; Kelly MP; Kirshner JR; Giurleo JT; Ehrlich G; Han AQ; Thurston G; Olson WC; Zanzonico PB; Larson SM; Carrasquillo JA
    Mol Pharm; 2018 Jun; 15(6):2133-2141. PubMed ID: 29684277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody Coadministration as a Strategy to Overcome Binding-Site Barrier for ADCs: a Quantitative Investigation.
    Singh AP; Guo L; Verma A; Wong GG; Thurber GM; Shah DK
    AAPS J; 2020 Jan; 22(2):28. PubMed ID: 31938899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imaging and Monitoring HER2 Expression in Tumors during HER2 Antibody-Drug Conjugate Therapy Utilizing a Radiolabeled Site-Specific Single-Domain Antibody Probe:
    Ge S; Wang C; You X; He H; Zhang B; Jia T; Cai X; Sang S; Xu T; Deng S
    J Med Chem; 2024 Aug; 67(15):12855-12867. PubMed ID: 39077778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity.
    Yao X; Jiang J; Wang X; Huang C; Li D; Xie K; Xu Q; Li H; Li Z; Lou L; Fang J
    Breast Cancer Res Treat; 2015 Aug; 153(1):123-33. PubMed ID: 26253944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-terminal selective conjugation method widens the therapeutic window of antibody-drug conjugates by improving tolerability and stability.
    Ko MJ; Song D; Kim J; Kim JY; Eom J; Sung B; Son YG; Kim YM; Lee SH; You WK; Jung J
    MAbs; 2021; 13(1):1914885. PubMed ID: 33904380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer.
    Abdollahpour-Alitappeh M; Lotfinia M; Bagheri N; Sineh Sepehr K; Habibi-Anbouhi M; Kobarfard F; Balalaie S; Foroumadi A; Abbaszadeh-Goudarzi G; Abbaszadeh-Goudarzi K; Abolhassani M
    J Cell Physiol; 2019 Mar; 234(3):2693-2704. PubMed ID: 30246298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.